Yang L, et al. - In this systematic analysis, researchers compared the efficacy and safety of irinotecan-containing doublet treatment and irinotecan monotherapy for patients with advanced gastric cancer (AGC). Irinotecan-containing doublet treatment was observed increasing progression-free survival and was tolerable as a second- line chemotherapy for AGC when compared to irinotecan monotherapy. However, doublet treatment neither significantly prolong overall survival compared to monotherapy, nor did it significantly increase the overall response rates and disease control rates, when compared to monotherapy. Furthermore, with the irinotecan-containing doublet treatment, an increase in the incidences of ≥ Grade 3 neutropenia and anemia was noted.